Abstract | OBJECTIVES: METHODS: RESULTS: Three out of four patients achieved a rapid clinical remission of the lesions within 4 to 6 weeks after rituximab therapy continuing at least for four months with a successful corticoid reduction till prednisolone 10 mg a day. One patient showed no remission of the skin lesions accompanied by increasing levels for ESR and CRP. CONCLUSIONS:
Rituximab treatment seems to be very effective in several cases of vasculitis-associated cutaneous ulcers in RA patients. However, the effectiveness of rituximab in cases with this indication remains to be shown in larger number of patients.
|
Authors | Gunter Assmann, Michael Pfreundschuh, Jan Voswinkel |
Journal | Clinical and experimental rheumatology
(Clin Exp Rheumatol)
2010 Jan-Feb
Vol. 28
Issue 1 Suppl 57
Pg. 81-3
ISSN: 0392-856X [Print] Italy |
PMID | 20412708
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Glucocorticoids
- Immunologic Factors
- Rituximab
- Prednisolone
|
Topics |
- Aged
- Antibodies, Monoclonal
(administration & dosage)
- Antibodies, Monoclonal, Murine-Derived
- Arthritis, Rheumatoid
(drug therapy)
- Drug Therapy, Combination
- Female
- Glucocorticoids
(administration & dosage)
- Humans
- Immunologic Factors
(administration & dosage)
- Middle Aged
- Prednisolone
(administration & dosage)
- Retrospective Studies
- Rituximab
- Skin Ulcer
(drug therapy, etiology)
- Treatment Outcome
- Vasculitis
(complications, drug therapy)
|